Incyte (INCY) Company Overview

In addition to Wall Street's predictions for Incyte's (INCY) earnings, take a look at forecasts for some important metrics to better understand how the company performed in the quarter that ended in December 2024.

INCY's earnings for the fourth quarter of 2024 are expected to increase due to higher sales of Jakafi and Opzelura.

Incyte (INCY) lacks the necessary mix of two important factors that could lead to a strong earnings report in the near future. Be ready for the main expectations.

INCY has performed well over the last year, thanks to positive data results and promising developments in its pipeline. We think there is still potential for more growth at the current levels.

The U.S. launch is anticipated for early February. Niktimvo is the first and only approved therapy for chronic GVHD that focuses on CSF-1R to help decrease inflammation and fibrosis. Key findings from the AGAVE-201 trial, which supported FDA approval, indicate that Niktimvo led to lasting improvements in all examined organs and among different patient groups.

This is a comparison of how Incyte (INCY) and Atara Biotherapeutics (ATRA) have done in relation to their industry this year.

Incyte is experiencing strong growth, mainly due to JAKAFI and OPZELURA, and this is expected to continue with the introduction of new products like MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts predict that Incyte's revenue will rise by about 10% each year until JAKAFI's patent runs out in 2028, but recent sales trends and new launches may exceed these forecasts. The company plans to introduce 10 significant products by 2030, with promising candidates such as INCB123667 and povorcitinib showing good results in clinical trials.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).